Trials / Completed
CompletedNCT00813241
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers
A Pilot, Open-Label, Randomized, Crossover, Pharmacokinetic Study Of Enhanced Bioavailability Formulations Of Celecoxib In Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A pharmacokinetic study in healthy volunteers to determine the relative bioavailability of three formulations of celecoxib to the approved formulation.
Detailed description
Pharmacokinetics
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | celecoxib reference formulation | 200 mg single oral dose of celecoxib tablets |
| DRUG | celecoxib test formulation A1 | 150 mg single oral dose of celecoxib A1 formulation tablets |
| DRUG | celecoxib test formulation B2 | 150 mg single oral dose of celecoxib B2 formulation tablets |
| DRUG | celecoxib test formulation C1 | 150 mg single oral dose of celecoxib Cl formulation tablets |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-03-01
- Completion
- 2009-03-01
- First posted
- 2008-12-23
- Last updated
- 2021-02-02
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT00813241. Inclusion in this directory is not an endorsement.